Oral mucositis: Time for more studies

Yesid Alvarado; Lisa A. Bellm; Francis J. Giles

doi:10.1080/1024533021000037216

Oral mucositis: Time for more studies

Yesid Alvarado, Lisa A. Bellm, Francis J. Giles

Department of Cancer Biology

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

21 Citations (Scopus)

Abstract

Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.

Original language	English
Pages (from-to)	281-289
Number of pages	9
Journal	Hematology
Volume	7
Issue number	5
DOIs	https://doi.org/10.1080/1024533021000037216
Publication status	Published - Oct 2002
Externally published	Yes

Keywords

Antimicrobials
Hemopoietic growth factors
Keratinocyte growth factors
Oral mucositis
Stem cell transplantation

Access to Document

10.1080/1024533021000037216

Cite this

@article{4daea52e022c461195dbc2d42b040872,

title = "Oral mucositis: Time for more studies",

abstract = "Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.",

keywords = "Antimicrobials, Hemopoietic growth factors, Keratinocyte growth factors, Oral mucositis, Stem cell transplantation",

author = "Yesid Alvarado and Bellm, \{Lisa A.\} and Giles, \{Francis J.\}",

year = "2002",

month = oct,

doi = "10.1080/1024533021000037216",

language = "English",

volume = "7",

pages = "281--289",

journal = "Hematology",

issn = "1024-5332",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Oral mucositis

T2 - Time for more studies

AU - Alvarado, Yesid

AU - Bellm, Lisa A.

AU - Giles, Francis J.

PY - 2002/10

Y1 - 2002/10

N2 - Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.

AB - Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.

KW - Antimicrobials

KW - Hemopoietic growth factors

KW - Keratinocyte growth factors

KW - Oral mucositis

KW - Stem cell transplantation

UR - https://www.scopus.com/pages/publications/0036818288

U2 - 10.1080/1024533021000037216

DO - 10.1080/1024533021000037216

M3 - Review article

AN - SCOPUS:0036818288

SN - 1024-5332

VL - 7

SP - 281

EP - 289

JO - Hematology

JF - Hematology

IS - 5

ER -

Oral mucositis: Time for more studies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this